COMMUNIQUÉS West-GlobeNewswire

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

29/04/2025 - 07:00

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc 1 , +12% USD) with core operating income 1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali [...]

New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine

29/04/2025 - 07:00

Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-morning sleepiness. Daridorexant improved next-morning sleepiness compared to placebo from as [...]

Santhera Publishes Agenda for its Annual General Meeting

29/04/2025 - 07:00

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, [...]

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update

29/04/2025 - 07:00

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney disease [...]

Le Conseil d'Administration de la Financière de Tubize nomme Bruno Holthof comme Président

29/04/2025 - 08:00

Le Conseil d'Administration de la Financière de Tubize nomme Bruno Holthof comme Président Suite à la décision de Gaëtan Hannecart de ne pas solliciter le renouvellement de son mandat d'administrateur lors de l' [...]

The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair

29/04/2025 - 08:00

The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair As Gaëtan Hannecart did not seek renewal of his director’s mandate at the general shareholders meeting held on April 25, 2025, the Board [...]

Solésence To Report First Quarter 2025 Financial Results and Host a Conference Call

28/04/2025 - 22:01

ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, [...]

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

28/04/2025 - 22:01

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and [...]

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

28/04/2025 - 22:01

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]

Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change

28/04/2025 - 22:05

WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth [...]

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

28/04/2025 - 22:05

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight [...]

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

28/04/2025 - 22:05

SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

28/04/2025 - 22:05

- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in [...]

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

28/04/2025 - 22:05

- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: [...]

LifeMD to Report First Quarter 2025 Financial Results on May 6

28/04/2025 - 22:05

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 [...]

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

28/04/2025 - 22:05

PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

28/04/2025 - 22:05

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]

GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025

28/04/2025 - 22:10

Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), 28 avril 2025 - GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique spécialisée dans l'amélioration de la vie des patients atteints de [...]

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

28/04/2025 - 22:10

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare [...]